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In vivo platebt aggregation and plasma 
catecholamines in acute myocardial infarction 
In vivo platelet aggregation assessed with the Filtragometer and potential correlates were 
compared among (1) patients with acute myocardial infarction (AM), (2) normal controls, (3) 
patients with acute chest pain in whom AMI was eventually ruled out (ROM), and (4) chronic 
outpatients (Cardiac Clinic group) with a history of myocardial infarction and/or angina pectoris. 
The measure was independent of sex, age, platelet count, immediate food intake, serum 
cholesterol, and triglyceride levels. The AMI group showed higher in vivo platelet aggregation 
than any of the other three groups (p < 0.01). Least in vivo aggregation was seen in the normal 
group. Despite lack of correlation with the platelet aggregation measure, plasma epinephrine and 
norepinephrine showed statistically significant differences between the AMI and each of the 
other three groups. Our data Support an association between Platelet function and AMI, although 
not necessarily a cause and effect relationship. (AM HEART J 104~1255, 1982.) 
Richard P. Sorkin, M.D., Joyce M. Tokarsky, B.S., Marla J. Huber-Smith, B.S., 
Jeanne F. Steiger, and Daisy S. McCann, Ph.D. Westland and Ann Arbor, Mich. 
The precise contribution of platelet function to the 
development of myocardial infarction remains to be 
defined. Many in vitro attempts to assess subtle 
differences in platelet activity from one individual 
to another are plagued with potential artifacts. 
Among these difficulties are the probable loss of the 
most fragile platelets incurred in the process of 
preparing platelet rich plasma, the use of exogenous 
aggregating agents, and the removal of the platelets 
from the influence of their intravascular environ- 
ment.’ 
Hornstra and ten Hoor’s Filtragomet& obviates 
some of the difficulties encountered by the conven- 
tional measurements of platelet activity and has 
been developed into a commercially available, com- 
pact instrument. We therefore set out to determine 
the relationship between this measure of what has 
been labelled as an “in vivo” platelet aggregation 
and acute myocardial infarction as well as with a 
number of plasma factors which might influence it. 
Statistically significant differences in this platelet 
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function were observed between patients with acute 
myocardial infarction and (1) normal controls, (2) 
patients with acute chest pain in whom acute myo- 
cardial infarction was subsequently ruled out, and 
(3) outpatient Cardiac Clinic patients with a history 
of myocardial infarction and/or angina pectoris. The 
relationships between in vivo platelet aggregation 
and serum cholesterol, triglyceride, and plasma cat- 
echolamine levels were tested. 
METHODS 
Platelet aggregation measurement. The measurement 
of in viva platelet aggregation was made with the commer- 
cially available Filtragometer (Fleischman Electronics 
Corp., Montclair, N.J.) following the manufacturer’s 
instructions. The instrument measures the concentration 
of preformed platelet aggregates in the subject’s circula- 
tion by recording the time required for those aggregates to 
occlude a 20 pm nickel filter as defined by development of 
a 5 mm Hg pressure differential across the filter.* The 
system was first rinsed with 3.6% citrate. A 19 gauge 
butterfly needle was then inserted into the subject’s 
antecubital vein with every effort made to minimize vein 
wall trauma. Twenty-five IU heparin per milliliter of 
blood were infused into the tubing immediately adjacent 
to the butterfly needle. The rate of withdrawal of blood 
was maintained constant at 2 ml/min by use of a Harvard 
pump. Twenty milliliters of blood was withdrawn for 
platelet counts and chemical analysis. The tubing was 
then connected to the mixing chamber of the instrument 
from which the heparinized whole blood was drawn 
through the nickel filter. If occlusion did not occur within 
600 seconds, the run was terminated and the result 
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Table 1. Interassay reproducibility of catecholamine pools they do not tolerate repeated freeze-thaw cycles, and no 
each measured the indicated number of times over a 2- to specimen assayed in this study was submitted to more 
3-month period than one such cycle. 
% coefficient 
Pool Catechol N Mean k 1 S.D. variation 
Study groups. The following study groups were 
defined. I-group N = 27 normal subjects without history 
or objective evidence of cardiovascular disease were drawn 
from our laboratory and hospital staff. IZ-group C = 23 
Cardiac Clinic patients (3 female, 20 male) who reported 
for medical follow-up at 3-month intervals because of a 
recent history of myocardial infarction and/or angina 
pectoris (age 55 -t 11 years, mean + SD). Ill-group 
AMI = 14 patients (4 female, 10 male) on admission to the 
Cardiac Care Unit in whom acute myocardial infarction 
(AMI) was subsequently confirmed by (1) a typical clinical 
history of acute chest pain, (2) evolving ECG changes 
diagnostic of acute myocardial infarction, and (3) elevated 
total plasma creatine kinase (CK) with positive MB bands 
(age 59 +- 11 years). Five of 14 patients had diabetes 
mellitus and 5 of 14 had a prior history of hypertension. 
IV-group ROMI = 16 patients (3 female, 13 male) on 
admission to the Cardiac Care Unit with acute chest pain 
in whom acute myocardial infarction was subsequently 
ruled out, based on the negative data obtained from the 
criteria outlined for the AM1 group above (age 56 ? 10 
years). Four of 16 patients were diabetic, 5 of 16 had a 
prior history of hypertension, V-group 1 wk AMI = six 
patients from group III above (two female, four male) in 
whom repeat studies were obtained 1 week after the acute 
myocardial infarction episode. The small number of 
patients in this group reflects the fact that the majority of 
patients at this point were on medications which interfere 
with platelet aggregation studies, plasma catecholamine 
analysis, or both (age 65 + 6 years). 
40181 NE 13 
E 12 
73080 NE 14 
E 15 
41381 NE 10 
E 10 
21081 NE 12 
E 10 
444.7 k 36.5 8.2 
398.0 f 51.7 12.9 
361.0 k 30.5 8.4 
30.6 ‘- 14.9 48.6 
339.2 +- 39.4 11.6 
55.1 + 18.0 32.7 
216.0 + 29.4 13.6 
32.6 + 11.4 35.0 
NE = norepinephrine; E =epinephrine. 
recorded as “over 600 seconds.” (Such values are rare in 
nonmedicated persons and were not incorporated into the 
statistical analysis.) 
Long-term reproducibility of platelet aggregation was 
assessed by repeated measurements, two to eight per 
subject, performed over a 2- to 32-week period in 10 
normal controls. Short-term reproducibility and the effect 
of food intake on aggregation was evaluated in eight 
control subjects who were studied in the fasting state 
between 9:00 and 10:00 A.M., 2 and 6 hours after a 
breakfast consisting of 2 eggs, bacon, toast and coffee; and 
24 hours later, again in the fasting state. To confirm that 
occlusion of the nickel filter is a function of platelet 
aggregates rather than of fibrin clots, the occluding mate- 
rial was examined microscopically using Wright’s stain. 
The response of the Filtragometer measure to the inges- 
tion of 260 mg of aspirin was assessed in 12 normal 
subjects. 
Catecholamine determination. Chemical data included 
serum cholesterol, triglyceride, and plasma catecholamine 
levels. The latter were determined by our modificatior+ 
of the Passon and Peuler single isotope derivative tech- 
nique.6 The intra-assay reproducibility for this procedure 
is 7.1% and 12.7% for norepinephrine and epinephrine, 
respectively. The interassay reproducibility is in part a 
function of the catecholamine concentrations (Table I) 
and should be reported for normal concentrations, not 
high concentrations > 600 pg/ml, as they often are. Anoth- 
er consideration in reporting catecholamine levels is the 
orthostatic position of the subject just prior to and during 
the period the blood is drawn. Norepinephrine means -t 
standard deviation for normal controls in our laboratory 
are 235 2 51, 333 -t 78, and 424 f 100 pg/ml for supine 
(n = 34), seated (n = 30), and standing (n = 11) subjects. 
The analogous plasma epinephrine concentrations are 
33 f 18, 48 F 34, and 54 f 30 pg/ml. Blood for plasma 
catecholamines was placed into cooled heparinized vacu- 
tainers containing glutathione (5 mM final concentration 
in blood). The blood and chemicals were mixed gently by 
inversion and centrifuged in the cold as soon as possible. 
While plasma catecholamines are stable stored frozen, 
Patients for groups AM1 and ROM1 were admitted to 
the study on a random basis within the following selection 
process. Any patient admitted into the Cardiac Care Unit 
with acute chest pain between the hours of 8:00 A.M. and 
4:00 P.M. on weekdays was included in the study provided: 
(1) he/she gave informed consent to participation in the 
study and (2) he/she could assure us that no known 
antiplatelet drug (aspirin, indomethacin, ibuprofen, dipy- 
ridamole, and sulfinpyrazone) had been taken during the 
preceding 5 days. The need for informed consent skewed 
the AM1 population to a preponderance of less compli- 
cated infarction, i.e., Killip class I and II. Admission to the 
Cardiac Clinic group (group C) was limited because the 
majority of this population was on drugs known or 
thought to affect platelet aggregation. 
From the point of view of catecholamine analysis it is 
important to note that in groups N and C blood was drawn 
from seated individuals, whereas in groups AMI, ROMI, 
and 1 wk AM1 blood was obtained from patients in the 
supine position. We therefore included in the data normal 
plasma norepinephrine and epinephrine values for 15 
subjects aged 31 k 6 years in the basal state, i.e., 7 A.M. 
fasting and still supine after 7 hours bed rest (group B). 
Statistics. The data were submitted to statistical anal- 
ysis of variance using the MIDAS program of the Univer- 
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N C AMI ROM1 1WK AMI 
GROUP 
Fig. 1. In vivo platelet aggregation (mean 2 S.E.M.) of the Normal (N), Cardiac Clinic CC!), Acute 
Myocardial Infarction (AMI), Myocardial Infarction Ruled Out (ROMI) and 1 week post-Myocardial 
Infarction (1 wk AMI) groups. 
sity of Michigan’s MTS computer. The group I wk AM1 
was eliminated from the computer analysis because the 
number of cases studied was small. The data are included 
in this report because they are indicative of the course 
followed by in vivo platelet aggregation subsequent to the 
acute event. 
RESULTS 
Control aggregation data. In vivo platelet aggrega- 
tion data for 27 normal controls, 14 men and 13 
women, averaged 363 + 23 seconds (mean + SEM 
unless noted otherwise) to filter occlusion time. 
There was no significant difference between the 
males (n = 14, age 39 +- 13 [mean f S.D.] years, 
platelet aggregation 375 + 30 seconds) and the 
females (n = 13, age 42 -t- 11 years, platelet aggrega- 
tion in seconds to filter occlusion time 350 + 35). 
For 10 normal controls, the reproducibility of the 
measure assessed by repeated measurements (two to 
eight per subject performed over a 2- to 32-week 
period) was 21.8% (coefficient of variation). Repro- 
ducibility of the measure for fasting subjects 
between 9:00 and 1O:OO A.M. on two consecutive 
mornings was 19.5 % . Reproducibility within a given 
24-hour period was not affected by food intake or 
time of day and was 18.5% for seven subjects. Data 
from the normal subjects were tested for bias related 
to sex and/or age. In these 27 cases no significant 
differences could be attributed to either of those two 
variables. Microscopic inspection of the occluding 
material using Wright’s stain confirmed that the 
mass consisted of platelets with some entrapped red 
and white blood cells. Twenty-four hours after 
ingestion of 260 mg of aspirin, 12 normal subjects 
showed an average increase of 42.2% in their filter 
occlusion time and hence a proportional decrease in 
their in vivo platelet aggregation. 
Platelet counts. Among the individuals tested, only 
one had a frankly abnormal platelet count of 739,000 
platelets/mm3. The filter occluded at 71 seconds; the 
case was not included in the statistical analysis. 
Platelet counts for the Normal, AMI, ROMI, and 
Cardiac Clinic groups were 288,000 +- 16,600; 
288,000 +- 27,700; 246,000 f 19,200; and 260,000 -t 
14,200 per mm3, respectively. Over the platelet 
count range 112,000 to 483,000/mm3, no statistically 
significant relationship was apparent between count 
and in vivo aggregation. 
Platelet aggregation data among groups. Compari- 
sons of in vivo platelet aggregation between the 
groups studied are shown in Fig. 1. Individual 
changes in in vivo platelet aggregation between the 
time of the AM1 and 1 week later are shown in Fig. 2. 
Significant differences at p < 0.01 confidence levels 











AMI lwk AMI 
Fig. 2. Individual changes in in vivo platelet aggregation 
between the acute phase of myocardial infarction and 1 
week later. Patient (a) reinfarcted and died 1 week after 
the second Filtragometer measurement. 
existed between the AM1 group and each of the 
other groups. Substantially lower aggregation 
(longer time required for occlusion) than for any 
other group was displayed by the Normal control 
group @ < 0.05). 
Blood lipids. Mean cholesterol levels for the Nor- 
mal, AMI, ROMI, and Cardiac Clinic groups were 
234 + 13, 225 f 19, 229 +- 27, and 244 +- 11 mg/dl, 
respectively. Triglyceride levels in these groups were 
149 f 19, 242 + 35, 199 + 38, and 208 -t 18 mg/dl, 
respectively. No significant correlations were seen 
between in vivo platelet aggregation and serum 
cholesterol or triglyceride levels. 
plasma catecholamines. The plasma catecholamine 
analysis showed significantly higher norepinephrine 
as well as epinephrine concentrations for the AMI 
group as compared to the other groups (Fig. 3). 
Despite the high catecholamine levels of the AM1 
group, there was no statistically significant correla- 
tion between either catecholamine levels individual- 
ly or their sum and platelet aggregation. 
DISCUSSION 
The Filtragometer appears to measure a real 
platelet function since (1) its nickel filter is occluded 
by platelets at the termination of the measure, (2) it 
responds as anticipated to aspirin inhibition of 
platelet activity, (3) it is relatively independent of 
immediate physiological fluctuations of plasma con- 
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stituents such as lipid concentrations and (4) it is 
reproducible albeit at a coefficient or variation of 
+- 19%. 
Over a decade ago, Jijrgensen et a1.7 demonstrated 
that transient platelet aggregates in the microcircu- 
lation of the myocardium of animals can cause 
arrhythmias and sudden death. Discovery of the 
roles played by thromboxane (TXA,) and prostacy- 
clin (PGI,) in platelet aggregation and vascular 
tissue physiology have increased the expectation 
that platelets play a crucial role in atherogenesis and 
its sequelae. 8,g However, direct evidence of this in 
the human disease has been difficult to formu- 
late. lo 
Previous studies. In part this may be due to the “in 
vitro” techniques generally used to assess platelet 
functions, which of necessity neglect to consider 
certain platelet populations as well as the interac- 
tion of platelets with vessel wall constituents and/or 
other formed elements of blood. Wu and Hoak” 
have attempted to circumvent the problem by for- 
malin fixing the formed elements of blood and then 
comparing the platelet count of a fixed aliquot of 
blood with that of an unfixed one. Using this 
technique they reported substantial increases in 
circulating platelet aggregates in acute myocardial 
infarction, acute cerebral vascular insufficiency, and 
acute peripheral arterial insufficiency as compared 
to normal controls, patient controls, patients with 
stable angina, and chronic peripheral arterial insuf- 
ficiency. Reports by other authors with this tech- 
nique have been contradictory, some supporting Wu 
and Hoak’s findings,12, I3 some unable to do ~0,‘~’ l5 
and some ambivalent.16 In a later publication Wu 
and Hoak17 confirmed their earlier findings by 
studying similar populations with a “spontaneous” 
platelet aggregation technique. 
Steele et al.,l* using conventional platelet aggrega- 
tion response curves over the range 0.5 to 2.0 pg 
ADP/ml, did not see significant differences between 
their controls and 21 men with chronic coronary 
artery disease. A number of other workers have used 
platelet aggregation response thresholds to serially 
diluted aggregating agents, usually ADP, to demon- 
strate changes in platelet activity from normal con- 
trol subjects to patients with cerebral vascular dis- 
ease, lg, 2o ischemic heart disease,21 angina pectoris,22 
and acute myocardial infarction.23 A cautionary note 
at the end of Zahavi and Dreyfuss’ discussionz3 
suggests that other acute stress situations such as 
stroke, pulmonary infarction, and acute severe 
infection may produce similar aggregation patterns 
to those observed in acute myocardial infarction. 
Increased platelet aggregation in AMI. Among the 
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Fig. 3. Mean plasma epinephrine and norepinephrine concentrations of the groups studied. B represents 
the group drawn in the basal stats (see text); for the other abbreviations see legend for Fig. 1. Blood was 
drawn from supine individuals for the basal, AMI, ROMI, and 1 wk AM1 groups and in the seated position 
for the Normal and Cardiac Clinic groups. 
relatively few data which have been published using 
Hornstra and ten Hoor’s Filtragometer are several 
lipid studies”-26 and a report of increased in vivo 
platelet aggregation in 15 patients with cardiovascu- 
lar events, 10 with AM1 and five with acute cerebro- 
vascular accidents.27 Our Filtragometer data support 
the concept that increased in vivo platelet aggrega- 
tion is associated with AM1 and is reflected not only 
at the site of the occlusion but in the peripheral 
circulation as well. Despite the significant difference 
obtained when the AM1 group is compared with the 
other groups, there is some overlap in individual 
values. This is especially true between the AM1 and 
the ROM1 groups. Thus, even though the ROM1 
group is a high risk group (in our population 14 out 
of 16 had a prior history of cardiovascular disease 
and/or systemic hypertension), it is nonetheless 
doubtful that high in vivo platelet aggregation is the 
cause of myocardial infarction, but does suggest that 
it may be a contributory factor to the course of a 
multifactorial disease. 
Plasma composition effects. Shortly before the 
interactions between platelet aggregation and TXA, 
and PGI, were elucidated, both Fleischman et al.%,25 
and Hornstra et al.% reported that replacement of 
approximately 500 calories per day of saturated with 
unsaturated fats (60% linoleate, C16:2) resulted in 
lowered in vivo platelet aggregation. We did not look 
into the potential of dietary manipulation of in vivo 
platelet aggregation but were interested in the 
immediate effect of feeding vs fasting, since we 
wanted to study AM1 and ROM1 groups as soon 
after admission to the Cardiac Care Unit as possible 
without consideration of recent food intake. We saw 
no difference. These data agree with the conclusion 
reached by Carvalho et al.% that in vivo platelet 
aggregation is a function of the platelets rather than 
of the immediate plasma composition. Specifically 
these authors demonstrated that platelets of 
patients with type II hyperlipoproteinemia aggre- 
gated to one twenty-fifth of the mean concentration 
of epinephrine and one third of the threshold dose of 
ADP and collagen, as compared to normal controls. 
Patients with type IV hyperlipoproteinemia did not 
show platelet hypersensitivity despite elevated 
serum triglyceride levels. Carvalho et al.28 were not 
able to induce abnormal aggregation behavior in 
normal platelets by 30 to 60 minute incubation with 
type II plasma. Platelet fatty acid composition may, 
however, play a role in hyperaggregability and myo- 
cardial infarction.29-31 Shattill et aL30 and Stuart et 
a1.31 have demonstrated hyperaggregability of plate- 
lets after incubation with lipid liposomes in which 
the cholesterol/phospholipid ratio was adjusted to 
1260 Sorkin et al. 
2.2:1, a condition which in vitro raises the platelet 
cholesterol content. 
Johnson et a1.32,33 have reported sex-linked differ- 
ences of platelet aggregation in animals and man. 
Among their human population these same authors 
showed increasing platelet responsiveness with 
increasing donor age. Measurement of preformed 
platelet aggregates in our normal group of 14 men 
and 13 women showed neither a sex- nor an age- 
related bias. 
Consideration of catecholamines. Comparisons 
between plasma catecholamine levels were made 
between our Normal and Cardiac Clinic groups, 
since both were drawn seated; and between our 
Basal, AMI, and ROM1 groups, since these were all 
drawn supine. The latter two groups were of partic- 
ular interest since they received identical treatment 
in terms of admission to and subsequent care in the 
hospital. No difference was seen between the Nor- 
mal and the Clinic groups but significant differences 
exist between the AM1 and the ROM1 groups 
(p < 0.025) for both norepinephrine and epineph- 
rine, and between either of these two groups and the 
Basal group 0, < 0.001). The difference in catechol- 
amine levels between the AM1 and the ROM1 groups 
must be ascribed to a difference in physiological 
stress between the two groups; emotional stress is 
presumably similar since the diagnosis of AM1 was 
not established or ruled out at the time our studies 
were performed. Despite the similarities between 
aggregation and catecholamine data in terms of 
differences between the various groups, no statisti- 
cally significant correlation was obtained between 
the two measures. Correlation between the Filtra- 
gometer results and the catecholamine data were not 
altered by the removal of six patients who had 
received drugs designed to interact with catechol- 
amine receptors. Videback et a1.34 were among the 
first to report elevation of total plasma catecholam- 
ines to 1000 +- 450 pg/ml (mean +- S.D.) in AMI. 
This figure compares reasonably well with ours, 
where the mean sum of plasma norepinephrine plus 
epinephrine was 845 pg/ml. The same is true of the 
mean control values, where we obtained 235 pg/ml 
compared to Videback’s 243 pg/ml. Videback et a1.34 
concluded that catecholamine levels were substan- 
tially below those which can induce arrhythmias in 
experimental myocardial infarction. They are also 
two to three orders of magnitude below threshold 
doses needed to promote platelet aggregation in in 
vitro systems. 
Conclusions. The Filtragometer technique for 
assaying platelet aggregation is an interesting one 
because results are obtained immediately and with a 
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minimum of sample manipulation. AM1 probably 
has a multifactorial etiology. Coronary occlusion due 
to platelet aggregates may play a critical role for a 
substantial number of myocardial infarctions, vaso- 
spasm for others, and still unidentified physiological 
factors for the remainder. Our data support the 
concept of an association between platelet function 
and AMI. They do not support the concept of a 
necessary cause-and-effect relationship but are com- 
patible with the hypothesis that in vivo platelet 
aggregation may contribute to the subsequent devel- 
opment and eventual size of the myocardial infarc- 
tion. The role of early intervention with drugs which 
inhibit platelet aggregation remains an area for 
future investigation. 
We thank Dr. Francisco Eng for stimulating our interest in this 

















Hampton JR, Michell JRA: Human blood coagulation, hae- 
mostasis and thrombosis. 2nd ed. Oxford, 1976, Blackwell 
Scientific Publications, p 536. 
Hornstra G. ten Hoor F: The filtraaometer: A new device for 
measuring platelet aggregation in venous blood of man. 
Thromb Diath Haemorrh 34:531, 1975. 
Michaels R, Huber-Smith MJ, McCann DS: Evaluation of 
transcendental meditation as a method of reducing stress. 
Science 192:1242, 1976. 
Lederman RP, McCann DS, Work B: Endogenous plasma 
epinephrine and norepinephrine in last trimester of pregnan- 
cy and labor. Am J Obstet Gynecol 129~5, 1977. 
Eng FWHT, Huber-Smith MJ, McCann DS: The role of 
sympathetic activity in normal renin essential hypertension. 
Hypertension 2:14, 1980. 
Passon PG, Peuler JD: A simplified radiometric assay for 
plasma norepinephrine and epinephrine. Anal Biochem 
51:618, 1973. 
Jorgensen L, Rowsell HC, Hovig T, Glynn MF, Mustard JF: 
Adenosine diphosphate induced platelet aggregation and 
myocardial infarction in swine. Lab Invest 17:616, 1967. 
Dusting GJ, Moncada S, Vane JR: Prostaglandins, their 
intermediates and precursors: Cardiovascular actions and 
regulatory roles in normal and abnormal circulatory systems. 
Prog Cardiovasc Dis 21:405, 1979. 
Harker LA, Ritchie JL: The role of platelets in acute vascular 
events. Circulation 62(suppl V):18, 1980. 
Schafer AI, Handin RI: The role of platelets in thrombotic 
and vascular disease. Prog Cardiovasc Dis 22:31, 1979. 
Wu KK, Hoak JC: A new method for the quantitative 
detection of platelet aggregates in patients with arterial 
insufficiency. Lancet 2:924, 1974. 
Mehta P, Mehta J: Platelet function studies in coronary 
artery disease. Evidence for enhanced platelet microthrom- 
bus formation activity in acute myocardial infarction. Am J 
Cardiol 43:757, 1979. 
Dougherty J, McIntyre N, Weksler BB: Assessment of plate- 
let activation in relation to acute thrombotic events. Blood 
46:1021, 1975. 
Prazich JA, Rapaport SI, Samples JR, Engler R: Platelet 
aggregate ratio-standardization of technique and test 
results in patients with myocardial ischemia and patients 
with cerebrovascular disease. Thromb Haemost 38:597, 
1977. 
Rohrer TF, Pfister B, Weber C, Imhof PR, Stucki P: Quanti- 
tative changes in platelet aggregation due to physiological 
and pathological factors and medication. Blut 36:21, 1978. 
Volume 104 
Number 6 Platelet aggregation and catecholamines in AMI 1261 
16. Guyton JR, Willerson JT: Peripheral venous platelet aggre- 
gates in patients with unstable angina pectoris and acute 
myocardial infarction. Angiology 28:695, 1977. 
17. Wu KK, Hoak JC: Spontaneous platelet aggregation in 
arterial insufficiency: Mechanisms and implication. Thromb 
Haemost 35:702, 1976. 
18. Steele PP, Weily HS, Davies H, Genton E: Platelet function 
studies in coronary artery disease. Circulation 48:1194, 
1973. 
19. Dougherty JH, Levy DE, Weksler BB: Platelet activation in 
acute cerebral ischaemia. Lancet 1:821, 1977. 
20. Walsh PN, Par&i FI, Corbett JJ: Platelet coagulant activities 
and serum lipids in transient cerebral ischemia. N Engl J 
Med 295:854, 1976. 
21. Salkv N. Dugdale M: Platelet abnormalities in ischemic heart 
disease. AmJ Cardiol 32:612, 1973. 
22. Frishman WH. Weksler B. Christodoulou JP. Glvnn. MF. 
Mustard JF: Reversal of abnormal platelet aggregability and 
change in exercise tolerance in patients with angina pectoris 
following oral propranolol. Circulation 50:887, 1974. 
23. Zahavi J, Dreyfuss F: An abnormal pattern of adenosine 
diphosphate induced platelet aggregation in acute myocardi- 
al-infarction. Thromb Diath Haem&rh 21:76, 1969.. 
24. Fleischman AI. Justice D. Bierenbaum ML. Stier A. Sullivan 
A: Beneficial effect of increased dietary linoleate upon in vivo 
platelet function in man. J Nutr l&5:1286, 1975. 
25. Fleischman AI, Bierenbaum ML, Justice D, Stier A, Sullivan 
A, Fleischman M: Titrating dietary linoleate to in vivo 
platelet function in man. Am J Clin Nutr 28:601, 1975. 
26. Hornstra G, Lewis B, Chait A, Karvonen MJ, Lewis B, 
Turpeinen 0, Vergroesen AJ: Influence of dietary fat on 
platelet function in man. Lancet 1:1155, 1973. 
27. Fleischman AI, Bierenbaum ML, Justice D, Stier A, Sullivan 
A: In oivo platelet function in acute myocardial infarction, 
acute cerebrovascular accidents and following surgery. 
Thromb Res 6:205, 1975. 
28. Carvalho ACA, Colman RW, Lees RS: Platelet function in 
hyperlipoproteinemia. N Engl 3 Med 290:434, 1974. 
29. Valles J, Aznar J, Santos MT: Platelet fatty acids in acute 
mvocardial infarction. Thromb Res 14:231. 1979. 
30. Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper 
RA: Platelet hypersensitivity induced by cholesterol incorpo- 
ration. J Clin Invest 55:636, 1975. 
31. Stuart MJ, Gerrard JM, White JG: Effect of cholesterol on 
production of thromboxane B, by platelets in vitro. N Engl J 
Med 302:6, 1980. 
32. Johnson M, Ramey E, Ramwell PW: Androgen-mediated 
sensitivity in platelet aggregation. Am J Physiol:Heart Circ 
Physiol l:H381, 1977. 
33. Johnson M, Ramey E, Ramwell PW: Sex and age differences 
in human platelet aggregation. Nature 253:355, 1975. 
34. Videback J, Christensen NJ, Sterndorff B: Serial determina- 
tion of plasma catecholamines in myocardial infarction. 
Circulation 46:846, 1972. 
NOTE: 
After December lOth, Address Manuscripts to: 
Dean T. Mason, M.D., Editor-in-Chief 
AMERICAN HEART JOURNAL, Editorial Office 
Cardiac Center, Cedars Medical Center 
Cedars South-Suite 0 
1295 N.W. 14th Street 
Miami, Florida 33125 
